Tumour suppressor genes and growth regulatory genes are frequent targets for methylation defects that can result in aberrant expression and mutagenesis. We have established a methylation map of the promoter region of the neuro®bromatosis (NF1) gene and demonstrated functional sensitivity for methylation at speci®c sites for the SP1 and CRE binding (CREB) proteins in the NF1 regulatory region. We evaluated the methylation status of CpG dinucleotides within ®ve promoter subregions in the human and mouse homologues of the neuro®bromatosis (NF1) genes. Three 5' subregions were found to be consistently methylated in all the tissues analysed. In contrast, DNA methylation was absent in the vicinity of the transcription start site bounded by SP1 recognition sequences. Gelshift assays showed that methylation speci®cally inhibits the CREB transcription factor from binding to its recognition site at the NF1 transcription start site. Furthermore, SP1 elements within the NF1 promoter are methylation sensitive, particularly when methylation is present on the antisense strand. We propose that for NF1 as with several other tumour suppressor genes, CpG methylation occurs in a complex, site-speci®c manner with the maintenance of a methylation-free promoter region bounded by SP1 binding sites that allow an accessible promoter to be retained. When these SP1 boundaries are breached, methylation can sweep in, rendering the promoter inaccessible for speci®c methylation-sensitive transcription factors and leading to a loss of functional integrity of the methylation-free CpG island.
Introduction
Regulation of eukaryotic gene expression is a complex process that involves both genetic and epigenetic levels of control. DNA methylation exerts its epigenetic eect on a small proportion of genomic cytosine residues contained within so-called CpG islands. Dierential DNA methylation at CpG islands that contain gene regulatory regions is known to contribute to the complex regulatory mechanisms governing eukaryotic gene expression (Bird, 1987; Laird and Jaenisch, 1994; Graessman and Graessman, 1993; Razin and Cedar, 1991; Barlow, 1993) . Variant methylation patterns at speci®c transcription-factor binding motifs within regulatory regions may result in temporal and tissuespeci®c patterns of gene expression (Issa et al., 1996a,b; Iguchi-Ariga and Schaner, 1989; Comb and Goodman, 1990; Clark et al., 1997; Mancini et al., 1998) . Particularly relevant in the context of cancer syndromes have been reports of methylation within promoter regions of tumour suppressor genes contributing to the multistage process of tumour progression (Laird and Jaenisch, 1994; Issa et al., 1996a,b; Mancini et al., 1998; Greger et al., 1989; Ohtani-Fujita et al., 1993) . Our laboratory has previously shown that in the BRCA1 gene, site-speci®c methylation at a putative CRE binding motif interferes with CREB binding, suggesting that aberrant DNA methylation at BRCA1 regulatory sequences may play a role in the transcriptional inactivation of this gene (Mancini et al., 1998) .
In the retinoblastoma gene (RB1), ATF-like and RBF transcription factors do not bind when CpGs within their recognition sequences are methylated (Ohtani-Fujita et al., 1993) . Recently, Gra et al. (1997) have described how multiple SP1 elements both upstream and downstream of transcription start sites are common features of many CpG islands. This group has generated detailed maps of methylation patterns anking the E-cad and VHL tumour suppressor genes and suggested that methylation boundaries established around CpG islands may be overridden by de novo methylation, contributing to tumour suppressor gene silencing in neoplasia. Together, all these results strongly support the hypothesis that aberrant CpG methylation in tumour suppressor gene promoters can inactivate such genes and lead to oncogenesis.
The neuro®bromatosis (NF1) tumour suppressor gene is constitutively expressed in most human and mouse tissues and acts as an important regulator of cell growth and dierentiation (Wallace et al., 1990; Daston and Ratner, 1992; Huynh et al., 1994) . NF1 mutations are responsible for the genetic disease of the same name, with its characteristic clinical phenotype of tumours originating from cells of the peripheral nervous system Riccardi, 1992; Riccardi et al., 1994) . The NF1 promoter lies within a CpG island where errors in DNA methylation patterns could potentially suppress NF1 expression and result in a tumour phenotype. The DNA sequence for approximately 5 kb of the human NF1 promoter has been determined and several putative transcription factor binding motifs have been identi®ed (Hajra et al., 1994; Purandare et al., 1996) . These motifs include a cAMP response element (CRE), multiple AP2 and SP1 binding sites within the CpG island, as well as a putative repressor element approximately 3 kb upstream of the NF1 transcription site (Hajra et al., 1994; Purandare et al., 1996) . The putative CRE is likely an important regulator of NF1 expression, since altered intracellular cAMP levels have been shown to stimulate mitosis in cultured Schwann cells and to induce a dierentiated phenotype associated with increased NF1 expression (Gutmann et al., 1993) . However, neither the CRE element nor the other putative regulatory elements within the NF1 promoter have been functionally characterized, and evidence for DNA methylation interfering with transcription factor binding at these sites has not been investigated previously.
Our objectives in this study were (a) to characterize constitutive methylation patterns within promoter subregions of the human NF1 gene and its mouse homologue, (b) to establish the functional status of several putative transcription factor binding motifs in the NF1 promoter region and (c), to determine whether methylation could alter the binding of these transcription factors to their respective DNA motifs. We have used the sodium bisulphite method to develop methylation pro®les within the NF1 gene (Andrews et al., 1996; Clark et al., 1994) , gel mobility shift and antibody supershift assays to con®rm the status of putative transcription factor binding motifs, and sitespeci®c methylation assays to determine the eect of DNA methylation on binding at these motifs. We have established that the NF1 CpG island is constitutively unmethylated in all tissues examined while three regions 5' to these CpG-rich promoter subregions are consistently methylated. The limit for methylation extending into the NF1 promoter appears to be demarcated by an SP1 motif approximately 150 bp upstream of the transcription start site. As well, the SP1 elements and the CREB binding site in the NF1 promoter are sensitive to site-speci®c DNA methylation.
Results

Methylation in the mouse Nf1 promoter region
DNA methylation in the mouse Nf1 gene was evaluated using the sodium bisulphite conversion protocol. Experiments were performed that focussed on a 279 bp subregion of the mouse Nf1 promoter (Figure 1 ). This subregion was chosen since it contains the transcription start site as well as several putative transcription factor binding motifs including a CRE (cAMP response) element an SRE (serum response) element, and a PRE (progesterone response) element (Hajra et al., 1994) . Genomic DNA was isolated from seven tissues (brain, heart, kidney, liver, lung, ovary, spleen and testes) and subjected to the sodium bisulphite protocol. A total of 93 clones of converted PCR product representing the seven tissues was analysed. This region includes 27 CpG's, 27 CpNpGs and 54 non-CpG or non-CpNpG cytosines ( Figure  1b) . The actual number of cytosines evaluated within the 279 bp fragment varied among clones, depending upon the amount of readable sequence. However, we 
Site-specific DNA methylation in the NF1 promoter DN Mancini et al found 85% of the cytosines and cytosine-containing motifs present in this region were available for analysis. A total of 7097 cytosines were analysed, including 1789 cytosines present in CpG dinucleotides, 1024 cytosines present in CpNpG trinucleotides and 4284 cytosines not associated with either type of motif (Table 2) . Table 2 indicates the number of clones per tissue and denotes the total number of CpG dinucleotides, CpNpGs trinucleotides, and non-CpG/CpNpG cytosine residues analysed per tissue. Our data shows that there were very few methylated cytosines within the 279 bp fragment of the promoter region in the Nf1 gene in any of the tissues analysed. Only ten of 4284 cytosines not present in CpG/CpNpG motifs (50.5%) were found to remain unconverted, and among these no common methylation site was seen. Similarly, only 5 of 1789 CpGs remain unconverted and again no common methylation site was apparent. The methylation status of CpNpG trinucleotides was also assessed, given the capacity of the methylating machinery in mammals to modify CpNpG sites through maintenance and de novo methylation pathways (Clark et al., 1994) . As was observed at CpG dinucleotides, few CpNpGs remain unconverted in these adult tissues (50.2%) and no common methylation sites were observed. Figure 3 shows results from a typical DNA sequencing gel comparing genomic DNA (Figure 3a ) with bisulphite-converted DNA sequence from the Site-specific DNA methylation in the NF1 promoter DN Mancini et al mouse promoter (Figure 3b ). All cytosines in the treated template have been converted by sodium bisulphite, indicating the unmethylated state of these residues. We also analysed DNA methylation in the mouse Nf1 coding region ( Figure 3c ) that shares high homology with exon 28 of the human NF1 gene. We have previously established that CpG dinucleotides in the human NF1 coding region are consistently methylated in a variety of tissues (Andrews et al., 1996) . The portion of mouse Nf1 that is homologous to human NF1 exon 28 possesses four CpG dinucleotides, three of which are also present in the human sequence. The majority of CpGs (88%) in all clones analysed are methylated in this area of the mouse Nf1 coding region (Figure 3c ). Therefore, the presence of cytosine methylation in the mouse Nf1 coding region is similar to that seen in the human NF1 coding region (Andrews et al., 1996) but diers markedly with the lack of methylation observed at CpGs in the mouse Nf1 promoter subregion we analysed.
Methylation in the human NF1 promoter region
For the methylation analysis of the human NF1 promoter region, total genomic DNA was isolated from human placenta, cultured ®broblasts, an MCF-7 cell line, as well as lymphocyte DNA isolated from healthy blood donors. Three neuroblastoma cell lines (90-4, 90-6, 90-10SK-n-SH) were also used for our methylation studies (kindly provided by Dr Andre Bernards; The et al., 1993) . Brie¯y, total RNA from several human neuroblastoma cell lines was assessed by blot analysis using a 5' NF1 cDNA probe, representing nucleotides 1748 to 2673 (Genbank accession number M89914). Two of the cell lines used in our study (90-4 and 90-10) were found to express little or no NF1 mRNA. The 90-6 cell line used in this study does express NF1 mRNA  and our RT ± PCR results, data not shown) and was used as a source of control DNA. Four subregions of the human NF1 promoter were evaluated using the sodium bisulphite conversion protocol ( Figure 2 ). Our study began with the analysis of a region homologous to that analysed in the mouse NF1 promoter. Subsequently, our analysis of the human NF1 promoter was extended beyond this subregion to include two proximal 5' regions (H1, H2)¯anking a putative repressor element (Purandare et al., 1996) as well as a region having a putative SP1 element (H3).
Regions H1 and H2 are located *4 kb upstream of the transcription start site. The H1 region was PCR ampli®ed to produce a product of 452 bp (from nucleotides [nts.] 73889 to 73437; Figure 2b ) and clones were analysed from normal placenta, lymphocyte DNA, breast carcinoma tissue and neuroblastoma cell line 90-6. A total of 4089 cytosines were analysed, including 188 cytosines within CpG dinucleotides, 1034 cytosines within CpNpG trinucleotides and 2867 cytosines not associated with either type of motif. We determined that in all samples analysed, this upstream region of the NF1 promoter was constitutively methylated (a representative sample is shown in Figure 4a ) at CpG motifs. We determined that the four readable CpGs analysed within this region (at nts. 73763, 73736, 73660, 73506; Figure 2b ) were methylated at 90, 92, 98 and 75% levels, respectively (average=89%).
Similarly, we determined that the H2 subregion of the human promoter located *120 bp downstream of the previous site, was also consistently methylated at all CpGs in all 25 clones analysed. A total of 2650 cytosines were analysed, including 100 CpGs, 675 CpNpGs and 2650 cytosines not associated with either type or motif. We determined (Figure 4b ) that all four CpGs analysed within this 417 bp region (at nts. 73208, 73082, 72982, 72942; Figure 2b ) were methylated at 100, 100, 88 and 88% levels respectively (average=94%).
We also assessed the methylation status of two subregions (H3;H4) of the NF1 promoter within the putative CpG island (ampli®ed with primers DR141/ 142 and DR164/48, respectively). Subregion H3 is located *1 kb from the transcription start site and contains an SP1 element we have designated as SP1#1 (Figure 2c ). Sodium bisulphite sequencing and PCR was performed on this region to generate a 518 bp product containing 13 CpGs. In total we analysed 36 clones and determined that 95% of the CpGs were found to be methylated (Figure 5a ). A total of 4176 cytosines were analysed, including 432 CpGs, 1476 CpNpGs and 4176 cytosines not associated with either type or motif. We were able to assess methylation at 12 of the 13 CpGs analysed within this 417 bp region (at nucleotide positions 71258, 71211, 71159, 71131, 71119, 71095, 71064, 71057, 71040, 71034, 71032 and 7931; Figure 2c ). These CpGs were methylated at levels ranging from 92 ± 100% (average=96%). Furthermore, two CpNpGs (located at nts. 71128 and 71048) were also found to be consistently methylated at levels of 86 and 94%, respectively. Next, we analysed subregion H4, a 450 bp fragment of the NF1 promoter that contains the transcription start site and a second putative SP1 site (designated SP1#2). In contrast to the previous regions we have described, none of the CpGs in any of the cloned DNA from this subregion were found to be consistently methylated 3' of the site of SP1 #2 (region H4s: ampli®ed with primers DR164 / 48; Figure 5b ). A total of 12 164 cytosines were analysed, including 2790 CpGs, 3064 CpNpGs and 6310 other cytosines. Three sites 5' to the Sp1 #2 element (at nt positions 7249, 7238, and 7234) were found to be methylated 16, 42 and 16% of the time, respectively (average=25%). The unmethylated region commenced approximately 100 bp upstream of the SP1 site and continued through this site. In the vicinity of the transcription start site methylation status was unequivocal. None of the 26 CpGs in the area of the transcription start site (region H4t: ampli®ed with primers DR55/48; Figure 5c ) were found to be methylated. This absence of methylation appears to extend past the transcription start site at least as far downstream as NF1 exon 1. These ®ndings of a methylation-free region in the human NF1 gene are consistent with our data showing unmethylated CpGs in the homologous promoter subregion of the mouse Nf1 gene (Figure 3) .
To summarize, our data show that regional methylation dierences occur with the human NF1 promoter. Methylation appears to extend from a region that is 4 kb 5' upstream of the NF1 transcriptional start site and continues to within 250 bp of this site. From this point, a methylationfree CpG island exists that includes most of the CpG island and appears to extend through exon 1. A lack of DNA sequence 3' to exon 1 does not allow us to de®ne the 3' limit of the unmethylated island, but our data suggest that at least 1.5 kb of the human NF1 promoter is unmethylated and may exist as a zone within which methylation-mediated transcriptional suppression could exert an eect.
Methylation and CREB binding
Our laboratory (Mancini et al., 1998) and others have previously shown site-speci®c eects of DNA methylation within the promoter regions of a variety of tumour suppressor genes. However, similar information concerning the NF1 gene has been lacking. Several putative transcription factor binding motifs are present in NF1, including a CRE (cAMP response) element and an SRE (serum response) element located 16 and 14 bases respectively from the transcription start site (Hajra et al., 1994) . We have shown previously that methylation abolishes CREB binding in the BRCA1 gene (Mancini et al., 1998) . Therefore, we sought to identify putative regulatory motifs in the NF1 promoter where methylation might exert its eect, by using gel mobility shift assays to determine the binding potential of proteins from neuroblastoma nuclear extracts to methylated and unmethylated oligonucleotides corresponding to the CpG-containing CRE element. Two sets of double stranded oligonucleotides containing the NF1 CRE element (see Table  1 ) were synthesized (one set methylated and the other set unmethylated) and utilized as probes for the gel mobility shift and competition assays. These probes were incubated with nuclear extracts derived from the 90-6 neuroblastoma cell line that is known to express neuro®bromin. Figure 6 presents the results of gel mobility shifts and competition assays using neuroblastoma nuclear extract and radiolabelled double-stranded oligonucleotides. Lanes 1 ± 6 represent binding reactions utilizing labelled unmethylated oligonucleotides as probes; lanes 7 ± 12 utilized labelled methylated oligonucleotide probes. Lanes 1, 7 and 13 represent free probe lanes where the labelled oligonucleotide was loaded in the absence of nuclear extract. Lanes 2 and 14 show a strong signal indicating a strong anity of the CRE protein for the unmethylated oligonucleotide. In contrast, lane 8 shows a signi®cant decrease in binding anity of the protein for the unmethylated oligonucleotide. The competition assays show that the unlabelled, unmethylated competitor (in 250-fold excess) eectively competes for binding with the labelled, unmethylated oligonucleotide in lanes 4 and 15. In contrast, similar excess amounts of unlabelled, methylated oligonucleotide (lanes 5 and 16) did not compete eectively for binding with the methylated oligonucleotide. Similarly, a nonspeci®c unlabelled oligonucleotide (cathepsin D) also failed to compete with the binding of the unmethylated DNA in lanes 6 and 12. Competition assays with the unmethylated oligos (lanes 10 ± 12), verifying the results from these experiments.
When antibody raised against the CREB protein was added to the binding reaction (lane 3) a supershift of the lower protein band appeared to occur since the lower of the two prominent bands seemed diminished in intensity. In the same reaction, the upper of the two bands in the same lane appeared to be more intense (arrowhead, lane 3). However, this shift was not Figure 6 Gel mobility shift and competition assays using CRE oligonucleotides and neuroblastoma cell extracts. Lanes 1 ± 6 represent binding reactions utilizing labelled unmethylated oligonucleotides as probes; lanes 7 ± 12 utilized labelled methylated oligonucleotide probes. Lanes 1,7 and 13 represent free probe lanes. Lanes 2 and 14 show a strong signal indicating a strong anity of the CRE protein for the unmethylated oligonucleotide. Lane 8 shows a signi®cant decrease in binding anity of the protein for the unmethylated oligonucleotide. Unlabelled, unmethylated competitor (in 250-fold excess) eectively competes for binding with the labelled, unmethylated oligonucleotide in lanes 4 and 15. Excess amounts of unlabelled, methylated oligonucleotide (lanes 5 and 16) did not compete eectively for binding with the methylated oligonucleotide. Lane 6: a nonspeci®c unlabelled oligonucleotide (cathepsin D). Competition assays with all the unlabelled oligos (lanes 10 ± 12), verifying the results from the other experiments. In lane 3, anti-CREB antibody causes a supershift of the lower protein band that is partially obscured by the preexisting upper protein band. Lane 17 shows the presence of excess unlabelled, methylated oligonucleotide that allows the supershift complex to be visualized, clearly con®rming the identity of this protein as a member of the CREB family. The presence of a novel band in these competition experiments (indicated with *, lanes 15 ± 17) is discussed in the text completely obvious since the antibody-protein complex was obscured by the preexisting upper protein band. To more clearly show this apparent supershift, we repeated the supershift experiment and included in the reaction mix an excess of the unlabelled, methylated oligonucleotide that we had previously shown would eectively compete away the upper band in the gelshift assay (lane 5). Lane 17 shows that the presence of this excess unlabelled, methylated oligonucleotide allowed the supershift complex to be visualized, clearly con®rming the identity of this protein as a member of the CREB family. In some experiments, (as seen in lanes 15 ± 17) a novel band appears in these competition experiments (indicated with the asterix). This band does occur as a faint band in other experiments we have performed, and we believe this band represents a minor protein component of the methylation complex that has overlapping reactivity with the CRE antibody, and that is most obvious in those gelshift experiments where we utilize higher amounts of protein extracts and excess quantities of oligonucleotide competitors (as in lanes 15 ± 17).
In summary, the results from our gel mobility shift and competition assays demonstrate that the oligonucleotides containing the putative NF1 CRE element are recognized by CREB protein and that this binding is exquisitely sensitive to DNA methylation in vitro.
Methylation and SP1 binding
Previous studies have shown that the SP1 transcription factor is critical for both transcription (Macleod et al., 1994; Brandeis et al., 1994; Holler et al., 1988; Worrad and Schultz, 1997) as well as for the maintenance of methylation-free status within CpGrich regions (Clark et al., 1997; Gra et al., 1997) . Analysis of the NF1 promoter using TFSEARCH localized several putative SP1 motifs. The identity of these two SP1 sites were con®rmed via gel mobility shift (Figures 7 and 8) using nuclear extracts from a neuroblastoma cell line . Approximately 6 mg of nuclear extract was added to radiolabelled unmethylated double-stranded oligonucleotides incorporating the SP1 recognition sequence GGGCGG (Table 1 ). Figure 7 shows gel shift and competition assays for SP1 #1 (similar data for SP1 #2 is not shown). In lane 1, the radiolabelled oligo was run in the absence of nuclear extract. Lane 2 shows an intense signal indicating a strong anity for protein to the unmethylated oligonucleotide. In lane 3, the SP1 antibody was added to the binding reaction and demonstrates a clear supershift. The competition assays show that the unmethylated unlabelled competitor (in 250-fold excess) eectively competes for binding with the labelled unmethylated probe (lane 4) while the non-speci®c unlabelled cathepsin D oligonucleotide failed to compete with the binding of the unmethylated DNA (lane 5).
A variety of transcription factors are impeded by the presence of DNA methylation within their recognition sequences (i.e. CREB; Iguchi-Ariga and Schaner, 1989; Comb and Goodman, 1990; Tate and Bird, 1993; Kovesdi et al., 1987; Watt and Molloy, 1988) . However, while SP1 had originally been shown to bind regardless of the methylation status of its binding site (Iguchi-Ariga and Schaner, 1989; Clark et al., 1997; Holler et al., 1988) , a recent paper has shown that SP1 binding can be abolished when the ®rst two cytosines on the antisense sequence strand are methylated (Clark et al., 1997) . We therefore performed similar experiments to further address SP1 binding in the NF1 promoter region. Oligonucleotides were synthesized that correspond to the sense and antisense strands of the two SP1 sites found within the NF1 promoter (located between nts 71222 to 71201: SP1 #1; and 7150 to 7128: SP1 #2; respectively). These oligonucleotides diered solely with respect to which cytosines were synthetically methylated. Methyl sidegroups were added to either the central CpG on the sense strand, the central CpG on the antisense strand, or to both cytosines within the CpCpG motif on the antisense strand. The individual single-stranded oligonucleotides (Table 1) were then annealed and radiolabelled in various combinations for the gel shift assays.
In Figure 8 , lanes 1 ± 8 represent binding reactions utilizing labelled oligonucleotides corresponding to Figure 7 Gel mobility shift and competition assays for SP1 #1 using nuclear extracts from a neuroblastoma cell line (90-6). In lane 1, the radiolabelled unmethylated oligonucleotide was run in the absence of nuclear extract. Lane 2 indicates a strong anity of the SP1 protein for the unmethylated oligonucleotide. In lane 3, the SP1 antibody was added to the binding reaction and demonstrates a clear supershift (arrow). The competition assay in lane 4 show that excess unmethylated unlabelled competitor eectively competes for binding with the labelled unmethylated probe. A nonspeci®c unlabelled probe (cathepsin D) failed to compete with the binding of the unmethylated DNA in lane 5 Sp1 #1 and lanes 9 ± 15 utilized labelled oligonucleotides incorporating the SP1 #2 site. Lanes 1 and 9 represent free probe lanes where the unmethylated labelled oligonucleotide was loaded in the absence of nuclear extract. In lane 2, the SP1 antibody was added to the binding reaction and demonstrates a clear supershift. Lanes 3 and 10 represent completely unmethylated oligonucleotides and show a strong signal indicating a solid anity of SP1 for its consensus sequence in the unmethylated state. Lanes 4 and 11 represent oligonucleotides where only the central CpG on the lower strand is methylated. In this instance, SP1 binding is maintained, albeit slightly decreased in intensity. Lanes 5 and 12 depict the binding reactions where both cytosines within the CpNpG motif on the antisense strand are methylated. In accordance with previous results (Clark et al., 1997) , methylation of both central cytosines on the antisense strand decreases SP1 binding signi®cantly. In lanes 6 and 13, only the central CpG on the top strand is methylated, and these lanes demonstrate the maintenance of SP1 binding. Lanes 7 and 14 represent oligonucleotides where the central CpGs on both the sense and antisense strands are methylated. Again, this methylation does not seem to impede SP1 binding. Finally, in lanes 8 and 15, SP1 binding is strikingly decreased when all three CpGs are methylated.
While SP1 appears to be insensitive to DNA methylation at the central CpG on either strand, methylation of both cytosines at the antisense CpCpG is particularly inhibitory to the binding of SP1 protein to this consensus sequence. This suggests that double stranded, site-speci®c DNA methylation at SP1 sites within the NF1 promoter may block the binding of this critical transcription factor, and may be one of a series of inactivating methylation changes (epimutations) in the NF1 gene leading to tumourigenesis.
Discussion
Epigenetic changes alter gene expression through dierent mechanisms, depending on whether methylation is present within the gene coding or non-coding regions. For example, methylation of exonic CpGs is considered to be a major contributor to point mutations due to the hypermutability of 5-methylcytosine. In fact, up to 30% of germ-line mutations leading to human genetic disease occur as C to T transitions at CpG dinucleotides which frequently result in protein truncating mutations (Mancini et al., , 1998 Rodenhiser et al., 1997; Cooper and Krawczak, 1989) . DNA methylation within gene regulatory regions, on the other hand, may mediate gene inactivation either by causing general alterations in chromatin con®guration or by interfering with the binding of transcription factors. Such changes in methylation patterns in promoters are known to result in temporal and tissue-speci®c patterns of gene expression, and have been observed during neoplastic transformation (Iguchi-Ariga and Schaner, 1989; Comb and Goodman, 1990; Clark et al., 1997; Mancini et al., 1998; Holler et al., 1988) . For example, DNA methylation can lead to gene silencing indirectly by recruiting clusters of methyl-binding proteins that exclude the transcriptional machinery from the DNA template (Clark et al., 1997) . In contrast, site-speci®c methylation can directly alter transcription, as has been shown with the retinoblastoma (Rb1) gene, where methylation at CpGs within Figure 8 Gel mobility shift experiments comparing protein binding to NF1 SP1 #1 and SP1 #2 using variably methylated oligonucleotides. Lanes 1 ± 8 represent binding reactions with labelled oligonucleotides corresponding to SP1 #1, whereas lanes 9 ± 15 utilized labelled oligonucleotide incorporating the SP1 #2 site. Lanes 1 and 9 represent free probe lanes where the unmethylated labelled oligonucleotide was loaded in the absence of nuclear extract. In lane 2, SP1 antibody was added to the binding reaction and demonstrates a clear supershift (open arrow). Lanes 3 and 10 demonstrate SP1 binding to both unmethylated SP1 oligonucleotides. Lanes 4 and 11 used oligonucleotides for which only the central CpG on the antisense strand is methylated and where binding of SP1 is maintained. Lanes 5 and 12 depict the binding reactions for which both cytosines within the CpNpG motif on the lower strand are methylated and where SP1 binding is signi®cantly decreased. In lanes 6 and 13, only the central CpG on the sense strand is methylated, and SP1 binding is maintained. Lanes 7 and 14 represent oligonucleotides where the central CpGs on both the sense and antisense strands are methylated and SP1 binding is not impeded. In lanes 8 and 15, all three CpG sites are methylated and SP1 binding is signi®cantly decreased. These results show that while SP1 binding is not aected when it occurs at either the upper or lower CpG of its recognition sequence, methylation of the CpCpG motif on the antisense strand signi®cantly inhibits SP1 binding CRE and RBF-1 regulatory elements impedes binding and dramatically reduces Rb1 expression (OhtaniFujita et al., 1993; Sakai et al., 1991) .
We evaluated methylation within one region of the mouse NF1 promoter and four regions of the human NF1 promoter (Figures 1 and 2) . Figure 9 illustrates that in the human NF1 promoter, methylation extends to *4 kb from the transcription start site and continues to within 100 bases of an SP1 site. From this point, the NF1 CpG island is unmethylated. The two regions analysed lie upstream of the human NF1 CpG island and¯ank a putative repressor element previously delineated (Purandare et al., 1996) . Gel mobility shift assays performed by that group con®rmed the presence of a low-anity protein binding at a 95 bp subregion residing 3.3 kbp upstream of the transcription start. Although the repressor element itself does not contain a CpG motif, we have determined that the regions surrounding this site are consistently methylated. The functional signi®cance of methylation in this region and its eect on binding has yet to be determined. However, methylation within non-CpG island regions is thought to contribute to the maintenance of a heterochromatinized state which precludes binding of transcription factors (Tate and Bird, 1993; Antequera et al., 1990; Nan et al., 1996) . Since it has been shown that CpG dinucleotides in bulk chromatin outside CpG-islands may become hypomethylated in some tumours, altered methylation within this NF1 region could compromise the gene's structural integrity and alter NF1 expression (Gra et al., 1997) .
In contrast, while upstream regions of the NF1 gene are methylated, methylation was not detected within the vicinity of the NF1 transcription start site in any of the human or mouse tissues examined. Analysis of DNA derived from the three neuroblastoma cell lines also displayed a lack of methylation within this region of the human promoter. Subsequent RT ± PCR analysis revealed that the NF1 gene is expressed within the 90-4 and 90-10 cell lines, albeit at low levels. This substantiates the correlation between constitutive (yet variable) expression of the NF1 gene (Wallace et al., 1990; Daston and Ratner, 1992; Huynh et al., 1994) and the absence of DNA methylation reported here. Therefore, we suggest that the downregulation of NF1 gene expression found in the 90-4 and 90-10 neuroblastoma cell lines is not likely due to the presence of methylation in the NF1 promoter.
We have previously shown that the BRCA1 CpG island is consistently unmethylated in normal tissues while aberrant methylation occurs in a proportion of tumour tissues examined (Mancini et al., 1998) . It is still unclear whether inappropriate methylation within the NF1 CpG island contributes to the genesis of NF1-associated tumours. However, our evidence from gel mobility shift and competition assays shows the capacity for aberrant methylation to abolish binding of proteins to the CRE (and/or SP1) elements in the NF1 promoter, in a manner consistent with tumourspeci®c patterns of aberrant methylation reported to occur in a variety of other tumour suppressor genes (Ohtani-Fujita et al., 1993) . In fact, such methylation eects as we have found at the NF1 CRE motif may be particularly relevant to NF1 gene expression, given the signi®cant eect that altered intracellular cAMP levels have in stimulating mitosis and inducing dierentiation along with increased NF1 expression in cultured Schwann cells (Gutmann et al., 1993) . As a result, we suggest that altered DNA methylation may be one of the events that could lead to transcriptional inactivation of the NF1 gene through the inhibition of speci®c interactions between critical transcription factors and their recognition sites. Such epigenetic modi®cation within the NF1 gene therefore may contribute to the diverse multifocal tumours common to the neurofibromatosis phenotype. As has been undertaken with other tumour-suppressor genes such as BRCA1 (Mancini et al., 1998) and RB1 (Ohtani-Fujita et al., 1993) , further studies are now warranted to determine whether a subset of NF1-associated tumours possess second-hit methylation defects at transcription factor elements such as CRE.
While altered gene expression may be a consequence of aberrant methylation in the NF1 gene, our data also prompted us to address the cellular mechanisms necessary to keep the NF1 promoter region methylation-free. Several studies in the literature point to a potential role for SP1 binding sites in maintaining the CpG island in an unmethylated and transcriptionally active state (Gra et al., 1997; Clark et al., 1997; Macleod et al., 1994; Brandeis et al., 1994) . In contrast to many other transcription factors, SP1 has until recently been shown to bind to its recognition sequence regardless of its methylation status. Our results show that SP1 binding is signi®cantly decreased upon methylation of the ®rst two cytosines on the lower strand of the SP1 recognition sequence. Evidence of methylation at the CpCpG motif of the SP1 recognition sequence in a proportion of retinoblastoma tumours further implicates methylation of speci®c CpGs in the multistage process leading to tumorigenesis (Clark et al., 1997) . We also found that in normal tissues, the SP1 site closest to the NF1 transcription start is unmethylated, and in fact, appears to establish the 5' limit for methylation within the CpG island. A lack of sequence 3' to NF1 exon 1 prevents us from evaluating the methylation status of any 3' SP1 sites Figure 9 Summary of results. The four analysed regions are shown as shaded boxes (numbered H1 to H4). The upstream regions of the NF1 promoter are found to be consistently methylated. In contrast, a region of hypomethylation is close proximity to the transcription start site exists that appears to be demarcated by the presence of the nearest 5' SP1 element immediately¯anking exon 1. However, our previous analysis of the human NF1 (Andrews et al., 1996) and BRCA1 (Mancini et al., 1998) coding regions has demonstrated the presence of methylation outside of the CpG island and we would predict that immediately downstream of exon 1 constitutive patterns of methylation would again be maintained.
Taken together, we suggest that CpG methylation in the NF1 promoter is under precise and complex control, with the inactivation of NF1 transcription occurring by both genetic and epigenetic mechanisms. We also suggest that any events that could preclude SP1 binding may contribute to the establishment of a hypermethylated state within the normally unmethylated NF1 CpG island. These events likely include: (a) methylation of speci®c CpGs within transcription factor binding motifs (such as the NF1 CRE site) thereby directly inhibiting factor binding and suppressing gene expression, (b) aberrant methylation of CpGs leading to the recruitment of methyl-CpG binding proteins that could sterically hinder the progression of the transcriptional machinery, (c) CpCpG methylation (on the alternate DNA strand) within SP1 recognition sequences such that binding of the SP1 protein was prevented, leaving the CpG island susceptible to widespread methylation and aecting multiple transcription elements and (d), methylation-induced mutagenesis at CpGs within the CpG island and/or coding region leading to premature protein truncation. Further studies are needed to address these events by making particular use of NF1-associated tumours, where altered methylation would provide evidence for epimutations in the multi-hit progression of NF1 tumorigenesis.
Materials and methods
DNA isolation and sodium bisulphite conversion
Mouse tissues used in this study (brain, heart, kidney, liver, lung, ovary, spleen and testes) were collected from adult BALB/c mice (6 ± 10 weeks) maintained in the animal care facility in the Department of Zoology, University of Western Ontario. Genomic DNA was also isolated from a variety of normal human tissues and from neuroblastoma cell lines established from NF1 patients and graciously provided to us by Dr Andre Bernards . Total genomic DNA was isolated (Sambrook et al., 1989) and modi®ed using the sodium bisulphite conversion protocol as previously described (Mancini et al., 1998; Andrews et al., 1996) . Brie¯y, 10 mg of genomic DNA was denatured with fresh 1 M NaOH (®nal concentration: 0.3 M) at 378C for 15 min then incubated overnight at 558C as previously described. Following this treatment, the template was cleaned, precipitated and dissolved in 50 ml double distilled H 2 O as previously described (Mancini et al., 1998) .
Polymerase Chain Reaction
In the subsequent PCR ampli®cation of the bisulphiteconverted genomic DNA, speci®c primers were constructed to generate fragments from the sense-strand of the converted mouse DNA, human DNA and DNA from the neuroblastoma cell lines. These primers are listed in Table 1a and are based on the Genbank sequence HSU17084. All PCR ampli®cations were performed in 25 ± 50 ml reactions containing 50 ± 150 ng of bisulphite-treated genomic DNA. The ampli®cation conditions were: 5 cycles at 948C (1 min), 55 ± 608C (2 min), 728C (3 min) followed by 25 cycles at 948C (1 min), 558 ± 608C (2 min), 728C (1 min). A ®nal 16 min soak (728C) was also performed. The PCR reactions werè hot-started' by adding 1 ml of the reverse primer to each of the individual samples during the initial 948C incubation period.
Cloning of PCR product
PCR product was cloned into either the pCRII TA or TOPO-TA cloning vectors (Invitrogen, San Diego, CA, USA). Individual positive clones were identi®ed and plasmid DNA was isolated by alkaline lysis (Sambrook et al., 1989 ) with a Promega WizardPlus Miniprep kit and sequenced with the T7 sequencing system (Pharmacia) using the forward primer of each primer pair. For each tissue examined, several clones were sequenced to allow the methylation status of all cytosine residues to be determined (including those within CpG dinucleotides and CpNpG trinucleotides). Cytosines present in CpGs, CpNpGs and as isolated cytosine residues were each scored. Bisulphite-converted templates were compared with unconverted genomic DNA to allow the methylation status of all cytosines to be determined. Unmethylated cytosines were characterized as those bands that were absent in the`C' lane and present in the`T' lane of the reactions from converted template. Any bands in the`C' lane of the sequenced converted DNA would indicate methylated cytosines (Mancini et al., 1998) .
Gel mobility shift and competition assays:
Gel mobility shift assays were performed to characterize sequence speci®c DNA-protein interactions within the NF1 promoter and subsequently, to determine if this binding was altered by the presence of methylated CpGs within the oligonucleotides. Oligonucleotides for gel mobility shift assays were prepared on an Applied Biosystems 380A DNA synthesizer and puri®ed according to the manufacturer's instructions. Methylated oligonucleotides were synthesized using 5'-dimethoxytrityl-5-methyl-2'-deoxycytidine, 3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (Glen Research, Sterling, VA, USA) to generate methylcytosine residues at the desired CpG motifs. All other non-cytosine CpGs were unmethylated. The double-stranded oligonucleotides were endlabelled with g-32 P-ATP (Amersham; 6000 Ci/ mmol, 1 Ci=37 GBq) using T4 polynucleotide kinase as described previously (Mancini et al., 1998; Archer et al., 1990) . Oligonucleotides were labelled to a speci®c activity of 1 ± 2610 5 c.p.m./pmol. The sequences of the methylated and unmethylated CRE-and SP1-containing oligonucleotides used in these experiments are given in Table 1 . Nuclear extracts were prepared from neuroblastoma cells as previously described (Mancini et al., 1998) and these nuclear extracts were stored at 7808C until use.
Competition assays compared the binding capacity of unmethylated and methylated probes alone and with an 250X excess of unlabelled/unmethylated and unlabelled/ methylated probes in separate reactions. An unrelated cathepsin D oligonucleotide was also utilized as a control in some experiments (sense: 5'-GGC CGC GCC CAC GTG ACC GGT-3'; antisense: 5'-ACC GGT CAC GTG GGC GCG GCC-3'; Wang et al., 1997) . All binding reactions contained 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 3 mM DTT, 10% glycerol, 0.05% NP40, 0.1 mM ZnCl 2 , 50 mg/mL poly (dI-dC), 10 5 c.p.m. of the double-stranded probes and 6 ± 10 mg of nuclear extract. Binding proceeded at room temperature for 20 min. Antibodies used in this study were purchased from Santa Cruz Biotechnology. The rabbit polyclonal anti-CREB-1 IgG or the goat polyclonal anti-SP1 IgG were added (1 ml) to the appropriate binding reaction in a total volume of 20 ml. The mixtures were then incubated for an additional 30 min at room temperature.
The samples were separated on 5% non-denaturing polyacrylamide gels and exposed to autoradiographic ®lm for 4 ± 16 h.
